The Oncologist, Vol. 12, No. suppl_1, 43-51, May 2007; doi:10.1634/theoncologist.12-S1-43 © 2007 AlphaMed Press
Pharmacologic Treatment of Cancer-Related FatigueaDepartment of Radiation Oncology, bDepartment of Family Medicine, cDepartment of Medicine, and dDepartment of Psychiatry, University of Rochester School of Medicine and Destistry, James P. Wilmot Cancer Center, Rochester, New York, USA Key Words. Cancer • Fatigue • Hematopoietic • Corticosteroids • Psychostimulants Correspondence: Jennifer Carroll, M.D., M.P.H., Department of Family Medicine, University of Rochester School of Medicine, Family Medicine Research Programs, 1381 South Avenue, Rochester, New York 14620, USA. Telephone: 585-506-9484 ext. 219; Fax: 585-473-2245; e-mail: Jennifer_Carroll{at}URMC.Rochester.edu
Fatigue is the most commonly reported symptom in patients with cancer, with a prevalence of over 60% reported in the majority of studies. This paper systematically reviews pharmacologic agents in the treatment of cancer-related fatigue (CRF). We conducted a literature review of clinical trials that assessed pharmacologic agents for the treatment of CRF. These agents include hematopoietics (for anemia), corticosteroids, and psychostimulants. Other therapeutic agents that are less well studied for CRF but are currently the focus of clinical trials include L-carnitine, modafinil, bupropion, and selective serotonin reuptake inhibitors such as paroxetine.
Disclosure of potential conflicts of interest is found at the end of this article.
This article has been cited by other articles:
Copyright © 2007 by AlphaMed Press. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||